From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

DoD Seeks New Drug for Alphaviruses

by Stephanie Lizotte
March 20, 2012

The Department of Defense (DoD) is soliciting proposals for small molecule drug candidates for treatment of or prevention against alphavirus-induced encephalitis.

Venezuelan Equine Encephalitis (VEEV), Eastern Equine Encephalitis Virus (EEEV), and Western Equine Encephalitis Virus (WEEV) are zoonotic mosquito-borne viruses that infect both equines and humans, and potentially cause significant morbidity and mortality. Since these viruses pose a serious threat to human health and are considered potential biological weapons, an urgent need exists under the Joint Chemical and Biological Defense Program for effective therapeutics against these agents.

In 1961, the U.S. Army developed a live-attenuated vaccine (TC-83) against VEEV; in 1974, the Army developed a formalin-inactivated form (C-84). TC-83 is used under Investigational New Drug (IND) status to immunize at-risk laboratory personnel.  However, the vaccine has several limitations: approximately 23% of vaccinated people develop flu-like symptoms; an additional 18% do not respond to the vaccine and need a boost with C-84. Furthermore, current medical measures might not effectively address non-biological routes of exposure or genetic modifications. 

The ultimate goal of the program is to rapidly deliver qualified small molecule inhibitors against at least one alphavirus. The program will be administered in stages starting with small animal studies through non-human primate safety and pharmacokinetic studies and into a Phase I clinical trial.  Due to the complex and unprecedented nature of small molecule drug discovery and development against this class of viruses, the government encourages team arrangements as appropriate.

The effort is newly listed as Rapid Innovation Topic Number: CBO-ALPHA-01 under existing Defense Threat Reduction Agency (DTRA) Broad Agency Announcement HDTRA1-12-CHEM-BIO-BAA.

From Our Partners
Tags: BAADefense Threat Reduction AgencyMosquito-Borne

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC